GSK lines up a shot at a block­buster mar­ket as new CEO pre­pares to tack­le Mer­ck ri­val head on

New Glax­o­SmithK­line CEO Em­ma Walm­s­ley is one big step clos­er to tak­ing a shot at a block­buster mar­ket­ing pro­gram to­day af­ter an FDA pan­el re­view end­ed with a unan­i­mous thumbs up for their new shin­gles vac­cine.

GSK earned some glow­ing praise on Wednes­day as the ad­vi­so­ry group looked at a vac­cine that just a few months ago proved it could gen­er­ate a pro­tec­tive re­sponse in pa­tients al­ready jabbed with Mer­ck’s Zostavax, a $759 mil­lion earn­er last year that is the on­ly prod­uct for this in­di­ca­tion now on the mar­ket. That’s sig­nif­i­cant as the ef­fect of Zostavax is al­so known to wane over time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER